Activity of nab-paclitaxel in a heavily-pretreated breast cancer patient who experienced a change of tumour biology
The patient described here was diagnosed with hormone-receptor-positive breast cancer and underwent numerous treatments in the neoadjuvant, adjuvant and palliative settings. Metastatic disease occurred that was confined to the bone, but kept progressing over several years. Due to the short-lasting nature of the patient’s responses to various endocrine agents, a re-biopsy was performed and a hormone receptor switch to triple negativity was established. With nab-paclitaxel therapy, disease stabilisation has been achieved for 8 months. The patient has tolerated this therapy very well in spite of massive pretreatment.